RALGAPA1 Antibody / Ral GTPase-activating protein subunit alpha-1, 100 ug

RALGAPA1 antibody detects Ras-related protein Ral GTPase-activating protein subunit alpha-1, a large scaffolding and regulatory protein that modulates RalA and RalB small GTPase activity. Encoded by the RALGAPA1 gene on chromosome 14q13.2, this protein forms part of the heterodimeric RalGAP complex together with RALGAPB, acting as a GTPase-activating protein (GAP) that inactivates Ral GTPases by promoting GTP hydrolysis. Through this mechanism, RALGAPA1 negatively regulates Ral-mediated signaling pathways involved in vesicle trafficking, cytoskeletal dynamics, and cell proliferation.

RALGAPA1 localizes to the cytoplasm and membranes, where it integrates signals from Ras and Ral GTPase pathways. By controlling RalA and RalB activity, RALGAPA1 influences exocyst complex formation, endocytosis, and autophagy. Loss or suppression of RALGAPA1 enhances Ral GTPase activation and promotes tumorigenesis, cell motility, and invasion. In neurons, RALGAPA1 contributes to vesicular transport and synaptic regulation, while in muscle tissue it participates in trafficking of insulin-responsive vesicles. Mutations in RALGAPA1 have been associated with neurodevelopmental delay and epilepsy, underscoring its importance in neuronal signaling.

The RALGAPA1 antibody is used in signal transduction, neurobiology, and cancer research to investigate Ral GTPase regulation and membrane trafficking. Western blot analysis identifies a 190 kilodalton band corresponding to the alpha subunit of the RalGAP complex, while immunofluorescence reveals cytoplasmic and membrane-associated staining. This antibody enables detailed characterization of RALGAPA1 expression and function in signaling networks that intersect Ras and Rho GTPase pathways.

Mechanistically, RALGAPA1 serves as a key inhibitor of Ral-dependent pathways that link receptor tyrosine kinases to exocytosis and cytoskeletal remodeling. Its GAP activity provides spatial and temporal control over Ral signaling to prevent aberrant growth or migration. The RALGAPA1 antibody is essential for studying how deregulation of RalGAP signaling contributes to cancer progression and neurological dysfunction. NSJ Bioreagents offers this antibody validated for its applications, for reliable use in human and model systems.